Moderna Reaffirms Its 2024 Expected Revenue Of Approximately $4B, Versus Consensus Of $4.21B From Its Respiratory Franchise, And Now Expects Approximately $0.3B In Net Sales In 1H 2024, Reflecting The Seasonality Of The Respiratory Business
Portfolio Pulse from Benzinga Newsdesk
Moderna has reaffirmed its 2024 revenue forecast for its respiratory franchise at approximately $4B, slightly below the consensus estimate of $4.21B. The company also expects around $0.3B in net sales for the first half of 2024, highlighting the seasonal nature of the respiratory business.
May 02, 2024 | 10:37 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna reaffirms its 2024 revenue expectation for its respiratory franchise at $4B, below the consensus of $4.21B, with $0.3B expected in 1H 2024 sales.
Moderna's reaffirmation of its 2024 revenue forecast being lower than the consensus estimate could lead to negative investor sentiment in the short term. The explicit mention of seasonality affecting first-half sales further emphasizes the challenges in meeting higher market expectations, potentially impacting the stock negatively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100